NEW—First full results from interim analysis confirm that the Oxford #COVID19 vaccine is safe and efficacious against symptomatic COVID-19 disease: hubs.li/H0CcSs60 (1/6)
The vaccine protects against symptomatic disease in 70% of cases – with vaccine efficacy of 62% for those given two full doses, and of 90% in those given a half then a full dose. (2/6)
The first clinical efficacy results of the vaccine are based on a pre-specified pooled analysis of phase 3 trials in UK and Brazil (11,636 people), alongside safety data from 23,745 participants in 4 trials in the UK, Brazil and South Africa. (3/6)
Only three out of 23,745 participants over 3.4 months experienced serious adverse events: 1 in vaccine group, 1 in control group & 1 remains masked to group allocation. All participants have recovered, or are recovering, and remain in the trial. (4/6)
Secondary outcomes suggest the vaccine may also protect against asymptomatic infection – vaccine efficacy of 4% for those given two full doses, and of 59% in those given a half then a full dose. However, findings need to be confirmed. (5/6)
As more data becomes available, authors will investigate differences in subgroups such as older adults, various ethnicities, doses, timing of booster vaccines, and will determine which immune responses equate to protection from infection or disease. (6/6)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
NEW—Radiotherapy following prostate cancer surgery can safely be avoided for many men: finding from a prospectively planned systematic review & meta-analysis assessing results from 2153 men enrolled across 3 trials, with median follow-up of at least 5 yrs hubs.li/H0x3LxP0
NEW—Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial hubs.li/H0x5PXH0 (Trial 1/3)
NEW—Adjuvant radiotherapy vs early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial @TheLancetOncol (Trial 2/3) hubs.li/H0x69kT0
NEW Editorial discusses the enormous effect that #COVID19 has had on scientific publishing as well as the increased public interest in & scrutiny of research & science hubs.li/H0wwv5L0
In recognition of #PeerRevWeek20 we would like to say thank you to our reviewers for their essential role in maintaining the advancement of science and medicine through helping us to identify the most robust and impactful work #TrustInPeerReviewhubs.li/H0wB2cg0
From peer review, through our in-house editing process, production, to publication and beyond, the entire Lancet team brings a wealth of expertise in scholarly publishing
Non-communicable diseases & injuries (NCDI) cause more death & disability at every age among the world’s poorest billion than in wealthy countries— new @NCDIpoverty Commission provides cost-effective & equitable interventions to address #NCDIPovertyhubs.li/H0wd1XP0
Among the world’s poorest people, almost 800,000 under age 40 die each year from #NCDs & injuries
The @NCDIpoverty Commission outlines how to reverse the neglect of the world’s most marginalised people living with these conditions #NCDIPovertyhubs.li/H0wd1XP0
"Partnerships & coalition building will be key not only within the #NCD community but also in alliances forged with the UHC & anti-poverty movements"—The Lancet Editors reflect on the #NCDIPoverty Commission calling for expansion of the global NCD agenda hubs.li/H0wfQsN0
New research mapping global trends in vaccine confidence across 149 countries between 2015-19 & based on data from over 284,000 adults surveyed about their views on whether vaccines are important, safe and effective, reveals vaccine hesitancy hotspots hubs.li/H0w0gKb0
Findings from largest study of global vaccine confidence to date finds that although confidence remains low across Europe, there are signs that it is increasing for much of Europe, including France hubs.li/H0w0gKb0
Largest global vaccine confidence survey suggests that overall confidence in vaccines—including safety, effectiveness, and importance—fell in Indonesia 🇮🇩, the Philippines 🇵🇭, Pakistan 🇵🇰, and South Korea 🇰🇷 between Nov 2015 and Dec 2019 hubs.li/H0vXTbc0
NEW—Preliminary results from Russian trials find that #COVID19 vaccine candidates led to no serious adverse events and elicit antibody response hubs.li/H0vGWRW0
Thread (1/8)
The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part #COVID19 vaccine (2/8)
The two-part #COVID19 vaccine included two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S) (3/8)
#COVID19 is a pandemic that must highlight the high burden that #NCDs place on health resources, but also that many of the tools required to fight a pandemic are also required to fight #NCDs. NEW Editorial ahead of #UNGA & @ncdalliance#ActOnNCDs Week hubs.li/H0vG-Mk0
NEW—Among high-income countries, only
Denmark 🇩🇰
Luxembourg 🇱🇺
New Zealand 🇳🇿
Norway 🇳🇴
Singapore 🇸🇬
South Korea 🇰🇷